CY1107674T1 - Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων - Google Patents

Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων

Info

Publication number
CY1107674T1
CY1107674T1 CY20071100794T CY071100794T CY1107674T1 CY 1107674 T1 CY1107674 T1 CY 1107674T1 CY 20071100794 T CY20071100794 T CY 20071100794T CY 071100794 T CY071100794 T CY 071100794T CY 1107674 T1 CY1107674 T1 CY 1107674T1
Authority
CY
Cyprus
Prior art keywords
long
term
pharmaceutical combination
protector
therapeutic treatment
Prior art date
Application number
CY20071100794T
Other languages
English (en)
Inventor
Wolfgang Baiker
Ludwing Mehlburger
Original Assignee
Boehringer Ingelheim Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29271571&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1107674(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2002118392 external-priority patent/DE10218392A1/de
Priority claimed from DE2002118611 external-priority patent/DE10218611A1/de
Application filed by Boehringer Ingelheim Pharma Gmbh & Co. Kg filed Critical Boehringer Ingelheim Pharma Gmbh & Co. Kg
Publication of CY1107674T1 publication Critical patent/CY1107674T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε ένα νέο φαρμακευτικό συνδυασμό για τη θεραπευτική αντιμετώπιση της καλοήθους υπερπλασίας του προστάτη (ΒΡΗ) ή για την μακροπρόθεσμη πρόληψη της οξείας επίσχεσης ούρων.
CY20071100794T 2002-04-24 2007-06-14 Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων CY1107674T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2002118392 DE10218392A1 (de) 2002-04-24 2002-04-24 Verwendung von Arzneimittelkombinationen zur Behandlung von benigner Prostatahyperplasie
DE2002118611 DE10218611A1 (de) 2002-04-25 2002-04-25 Verwendung einer Tamsulosin enthaltenden Arzneimittelkombination zur Behandlung von benigner Prostatahyperplasie
EP03725053A EP1501517B1 (en) 2002-04-24 2003-04-17 Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for the long-term prevention of acute urinary retention

Publications (1)

Publication Number Publication Date
CY1107674T1 true CY1107674T1 (el) 2013-04-18

Family

ID=29271571

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20071100794T CY1107674T1 (el) 2002-04-24 2007-06-14 Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων

Country Status (22)

Country Link
US (2) US20030225118A1 (el)
EP (2) EP1743656A3 (el)
JP (1) JP2005524693A (el)
CN (1) CN1646135A (el)
AT (1) ATE361075T1 (el)
AU (1) AU2003227643A1 (el)
BR (1) BR0309435A (el)
CA (1) CA2479992A1 (el)
CY (1) CY1107674T1 (el)
DE (1) DE60313603T2 (el)
DK (1) DK1501517T3 (el)
EA (1) EA008377B1 (el)
ES (1) ES2287474T3 (el)
HR (1) HRP20040994A2 (el)
IL (1) IL163976A0 (el)
MX (1) MXPA04010408A (el)
NO (1) NO20044333L (el)
NZ (1) NZ536514A (el)
PL (1) PL371430A1 (el)
PT (1) PT1501517E (el)
RS (1) RS92304A (el)
WO (1) WO2003090753A1 (el)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04010408A (es) * 2002-04-24 2005-02-17 Boehringer Ingelheim Pharma Combinacion farmaceutica para el tratamiento de hiperplasia prostatica benigna o para la prevencion a largo plazo de la retencion urinaria aguda.
RU2006119331A (ru) * 2003-11-03 2007-12-27 БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ АГОНИСТ β3-АДРЕНОРЕЦЕПТОРА, α-АНТАГОНИСТ И/ИЛИ ИНГИБИТОР 5α-РЕДУКТАЗЫ
CN101452893B (zh) * 2003-11-14 2011-04-13 株式会社半导体能源研究所 显示装置及其制造法
WO2006055659A2 (en) * 2004-11-15 2006-05-26 Smithkline Beecham Corporation Fixed dose combination op dutasteride and tamsulosin
CN102309495A (zh) * 2010-06-30 2012-01-11 北京润德康医药技术有限公司 一种复方制剂及其制备方法
WO2012110092A1 (en) 2011-02-17 2012-08-23 Synthon Bv Tamsulosin derivatives
BRPI1103204A2 (pt) * 2011-06-03 2014-02-25 Eurofarma Lab S A Composição farmacêutica para o tratamento de hiperplasia prostática benigna
WO2013123965A1 (en) 2012-02-20 2013-08-29 Synthon Bv A fixed dose pharmaceutical formulation
US10596127B2 (en) 2013-03-14 2020-03-24 Wellesley Pharmaceuticals, Llc Composition for reducing the frequency of urination, method of making and use thereof
BR102013020508B1 (pt) * 2013-08-12 2021-01-12 Ems S/A. Forma de dosagem que compreende um inibidor de esteroide 5-alfa-redutase e um bloqueador alfa, processo para a preparaçãode uma forma de dosagem e uso da forma de dosagem
EP2949319A1 (en) 2014-05-26 2015-12-02 Galenicum Health S.L. Pharmaceutical compositions comprising an active agent
EP3355877A4 (en) * 2015-09-30 2019-05-15 Wellesley Pharmaceuticals, LLC COMPOSITION FOR REDUCING URINATION FREQUENCY, METHOD FOR THE PREPARATION AND USE THEREOF
US10172910B2 (en) * 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
CN115969860A (zh) * 2021-10-14 2023-04-18 上海汇伦医药股份有限公司 一种药物组合物及其用途

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5391825A (en) * 1980-02-08 1995-02-21 Yamanouchi Pharmaceutical Co., Ltd. Sulfamoyl substituted phenethylamine intermediates
JPS56110665A (en) 1980-02-08 1981-09-01 Yamanouchi Pharmaceut Co Ltd Sulfamoyl-substituted phenetylamine derivative and its preparation
NZ211145A (en) 1984-02-27 1988-10-28 Merck & Co Inc 4-aza-5-alpha-androst-1-en-3-ones and pharmaceutical compositions
US4760071A (en) 1984-02-27 1988-07-26 Merck & Co., Inc. 17β-N-monosubstituted carbamoyl-4-aza-5α-androst-1-en-3-ones which are active as testosterone 5α-reductase inhibitors
US4772475A (en) 1985-03-08 1988-09-20 Yamanouchi Pharmaceutical Co., Ltd. Controlled-release multiple units pharmaceutical formulation
DE3888994T2 (de) 1987-04-03 1994-11-03 Merck & Co Inc Behandlung von androgener Alopecia mit 17-beta-n-mono-substituierten-carbamoyl-4-aza-5-alpha-androst-1-en-3-onen.
EP0285383B1 (en) 1987-04-03 1994-03-16 Merck & Co. Inc. Treatment of prostatic carcinoma with 17beta-n-monosubstituted-carbamoyl-4-aza-5alpha-androst-1-en-3-ones
IL101243A (en) * 1991-03-20 1999-12-22 Merck & Co Inc Pharmaceutical preparations for the treatment of benign prostatic hyperplasia containing steroid history
TW369521B (en) * 1993-09-17 1999-09-11 Smithkline Beecham Corp Androstenone derivative
TW382595B (en) 1993-10-15 2000-02-21 Merck & Co Inc Pharmaceutical composition for use in arresting and reversing androgenic alopecia
US6423719B1 (en) * 1999-02-16 2002-07-23 Upsher-Smith Laboratories, Inc. Method for treating benign prostate hyperplasia
AU7703700A (en) * 1999-09-22 2001-04-24 Merck & Co., Inc. Treatment of lower urinary tract symptoms and pharmaceutical compositions for use therein
MXPA04010408A (es) * 2002-04-24 2005-02-17 Boehringer Ingelheim Pharma Combinacion farmaceutica para el tratamiento de hiperplasia prostatica benigna o para la prevencion a largo plazo de la retencion urinaria aguda.

Also Published As

Publication number Publication date
DK1501517T3 (da) 2007-06-11
CA2479992A1 (en) 2003-11-06
EA200401340A1 (ru) 2005-06-30
EP1501517B1 (en) 2007-05-02
PT1501517E (pt) 2007-05-31
EP1501517A1 (en) 2005-02-02
US20030225118A1 (en) 2003-12-04
IL163976A0 (en) 2005-12-18
JP2005524693A (ja) 2005-08-18
PL371430A1 (en) 2005-06-13
NO20044333L (no) 2004-11-09
AU2003227643A1 (en) 2003-11-10
DE60313603D1 (de) 2007-06-14
ES2287474T3 (es) 2007-12-16
ATE361075T1 (de) 2007-05-15
BR0309435A (pt) 2005-02-15
WO2003090753A8 (en) 2004-11-04
EP1743656A2 (en) 2007-01-17
HRP20040994A2 (en) 2005-02-28
EA008377B1 (ru) 2007-04-27
DE60313603T2 (de) 2008-01-03
RS92304A (en) 2006-10-27
EP1743656A3 (en) 2007-03-07
WO2003090753A1 (en) 2003-11-06
CN1646135A (zh) 2005-07-27
MXPA04010408A (es) 2005-02-17
NZ536514A (en) 2006-11-30
US20070197666A1 (en) 2007-08-23

Similar Documents

Publication Publication Date Title
CY1107674T1 (el) Φαρμακευτικος συνδυασμος για τη θεραπευτικη αντιμετωπιση της καλοηθους υπερπλασιας του προστατη ή για την μακροπροθεσμη προληψη της οξειας επισχεσης ουρων
NO20034204L (no) Farmasöytiske kombinasjoner til behandling av kreft
CY1108714T1 (el) Ανταγωνιστες υποδοχεα cgrp
DE60023982D1 (de) System zur Behandlung von benigner Prostatahyperplasie
IL169685A0 (en) Treatment of benign prostatic hyperplasia using energolytic agents
NO993396D0 (no) Kinolin- ig kinolinforbindelser nyttige i terapi, spesielt i behandlingen av benign prostatisk hyperplasi
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
DK1373215T3 (da) Gelanamycinderivater egnet til behandling af cancer
NO20014560L (no) Quinasoliner og terapautisk anvendelse derav
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
DK1446012T3 (da) Bakteriolytisk kombinationsterapi til behandling af tumorer
EA200200306A1 (ru) Трициклические ингибиторы поли(адф-рибозо)полимераз
ATE408601T1 (de) Fredericamycin-derivate
NO20060398L (no) Anvendelse av en kombinasjon av en epidermal vekstfaktor reseptor kinase inhibitor og cytotoksiske midler for behandling og hemming av kreft
CY1107852T1 (el) Νεες χρησεις αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη της ημικρανιας
DE60025632D1 (de) Thrombopoietin-mimetika
NO20034780D0 (no) Antiangiogenisk kombinasjonsterapi for behandling av kreft
NO20054494L (no) Peptidvektorer
CY1106026T1 (el) Αρυλσουλφοναμιδια ως ανταγωνιστες της σepοτονινης για την αγωγη της παχυσαρκιας
PT1206444E (pt) Compostos que inibem a actividade da triptase
DK0986393T3 (da) Anvendelse af et nitroxid eller et prodrug heraf ved profylaktisk og terapeutisk behandling af cancer
EA200401100A1 (ru) 1α-ФТОР-25-ГИДРОКСИ-16,23E-ДИЕН-26,27-БИСГОМО-20-ЭПИХОЛЕКАЛЬЦИФЕРОЛ И ЕГО ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ
SE0004827D0 (sv) Therapeutic compounds
BR0307266A (pt) Compostos que inibem a atividade do fator xa
GB0301016D0 (en) Treatment of benign prostatic hyperplasia